A sirtuin activator and an anti-inflammatory molecule—multifaceted roles of adjudin and its potential applications for aging-related diseases

Seminars in Cell and Developmental Biology

Volumn 59, Issue , 2016, Pages 71-78

  Xia, Weiliang ^a   Geng, Keyi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Activator; Adjudin; Aging; Anti cancer; Anti inflammation; NF kB; SIRTUIN; Stroke

Indexed keywords

ADJUDIN; ANTIINFLAMMATORY AGENT; LONIDAMINE; SIRTUIN; SIRTUIN 3; UNCLASSIFIED DRUG; 1-(2,4-DICHLOROBENZYL)INDAZOLE-3-CARBOHYDRAZIDE; HYDRAZINE DERIVATIVE; INDAZOLE DERIVATIVE;

AGING; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN ISCHEMIA; CONTRACEPTION; DRUG POTENCY; HUMAN; MALE; NONHUMAN; REVIEW; ANIMAL; CHEMISTRY; DISEASES; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SPERMATOGENESIS;

AGING; ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE; HUMANS; HYDRAZINES; INDAZOLES; SIRTUINS; SPERMATOGENESIS;

EID: 84995694913     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2016.07.020     Document Type: Review

References (104)

1. [1] Cheng, C.Y., Silvestrini, B., Grima, J., Mo, M.-y.., Zhu, L.-j., Johansson, E., et al. Two new male contraceptives exert their effects by depleting germ cells prematurely from the testis. Biol. Reprod. 65 (2001), 449–461.
2. [2] Cheng, C.Y., Toxicants target cell junctions in the testis: insights from the indazole-carboxylic acid model. Spermatogenesis, 4, 2014, e981485.
3. [3] Grima, J., Silvestrini, B., Cheng, C.Y., Reversible inhibition of spermatogenesis in rats using a new male contraceptive, 1-(2, 4-dichlorobenzyl)-indazole-3-carbohydrazide. Biol. Reprod. 64 (2001), 1500–1508.
4. [4] Cheng, Y.-H., Xia, W., Wong, W.P., Xie, Q.R., Shao, J., Liu, T., et al. Adjudin-a male contraceptive with other biological activities. Recent Pat. Endoc. Metab. Immune Drug Discov. 9 (2015), 63–73.
5. [5] Chen, H., Mruk, D., Xia, W., Bonanomi, M., Silvestrini, B., Cheng, C., Effective delivery of male contraceptives behind the blood-testis barrier (BTB)-lesson from adjudin. Curr. Med. Chem., 2016.
6. [6] Mok, K.-W., Mruk, D.D., Lie, P.P., Lui, W.-Y., Cheng, C.Y., Adjudin a potential male contraceptive, exerts its effects locally in the seminiferous epithelium of mammalian testes. Reproduction 141 (2011), 571–580.
7. [7] Mruk, D.D., Wong, C.H., Silvestrini, B., Cheng, C.Y., A male contraceptive targeting germ cell adhesion. Nat. Med. 12 (2006), 1323–1328.
8. [8] Hu, G.X., Hu, L.F., Yang, D.Z., Li, J.W., Chen, G.R., Chen, B.B., et al. Adjudin targeting rabbit germ cell adhesion as a male contraceptive: a pharmacokinetics study. J. Androl. 30 (2009), 87–93.
9. [9] Corsi, G., Palazzo, G., Germani, C., Scorza Barcellona, P., Silvestrini, B., 1-Halobenzyl-1H-indazole-3-carboxylic acids: a new class of antispermatogenic agents. J. Med. Chem. 19 (1976), 778–783.
10. [10] Silvestrini, B., Palazzo, G., De Gregorio, M., Lonidamine and related compounds. Prog. Med. Chem. 21 (1984), 111–135.
11. [11] Floridi, A., Paggi, M.G., Marcante, M.L., Silvestrini, B., Caputo, A., de Martino, C., Lonidamine a selective inhibitor of aerobic glycolysis of murine tumor cells. J. Natl. Cancer Inst. 66 (1981), 497–499.
12. [12] Floridi, A., Paggi, M.G., D'Atri, S., De Martino, C., Marcante, M.L., Silvestrini, B., et al. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res. 41 (1981), 4661–4666.
13. [13] Di Cosimo, S., Ferretti, G., Papaldo, P., Carlini, P., Fabi, A., Cognetti, F., Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc.) 39 (2003), 157–174.
14. [14] Li, Y., Fung, K., Kwok, T., Lee, C., Suen, Y., Kong, S., Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells. Life Sci. 71 (2002), 2729–2740.
15. [15] Belzacq, A.-S., El hamel, C., Vieira, H., Cohen, I., Haouzi, D., Metivier, D., et al. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 20 (2001), 7579–7587.
16. [16] Calviño, E., Estañ, M.C., Simón, G.P., Sancho, P., del Carmen Boyano-Adánez M, de Blas E, et al Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK Akt/mTOR) modulation. Biochem. Pharmacol. 82 (2011), 1619–1629.
17. [17] Mathupala, S.P., Ko, Y.H., Pedersen, P.L., Hexokinase-2 bound to mitochondria: cancer's stygian link to the Warburg Effect and a pivotal target for effective therapy. Seminars in Cancer Biology, 2009, Elsevier, 17–24.
18. [18] Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009), 1029–1033.
19. [19] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
20. [20] Cervantes-Madrid, D., Romero, Y., Dueñas-González, A., Reviving lonidamine and 6-diazo-5-oxo-L-norleucine to Be used in combination for metabolic cancer therapy. BioMed. Res. Int., 2015, 2015.
21. [21] Assanhou, A.G., Li, W., Zhang, L., Xue, L., Kong, L., Sun, H., et al. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment. Biomaterials 73 (2015), 284–295.
22. [22] Oudard, S., Carpentier, A., Banu, E., Fauchon, F., Celerier, D., Poupon, M.F., et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 63 (2003), 81–86.
23. [23] Nya-Ngatchou, J.-J., Amory, J.K., New approaches to male non-hormonal contraception. Contraception 87 (2013), 296–299.
24. [24] Cheng, C.Y., Mo M-y Grima, J., Saso, L., Tita, B., Mruk, D., et al. Indazole carboxylic acids in male contraception. Contraception 65 (2002), 265–268.
25. [25] Cheng, C.Y., Mruk, D.D., The blood-Testis barrier and its implications for male contraception. Pharmacol. Rev. 64 (2012), 16–64.
26. [26] Chen, H., Mruk, D.D., Xia, W., Bonanomi, M., Silvestrini, B., Cheng, C.Y., Effective delivery of male contraceptives behind the blood-testis barrier (BTB) − lesson from adjudin. Curr. Med. Chem. 23 (2016), 701–713.
27. [27] Xia, W., Mruk, D.D., Lee, W.M., Cheng, C.Y., Unraveling the molecular targets pertinent to junction restructuring events during spermatogenesis using the Adjudin-induced germ cell depletion model. J. Endocrinol. 192 (2007), 563–583.
28. [28] Chen, K., Huang, Y.-h., Chen, J.-l., Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol. Sin. 34 (2013), 732–740.
29. [29] Munshi, A., Chloroquine in glioblastoma—new horizons for an old drug. Cancer 115 (2009), 2380–2383.
30. [30] Vazquez-Martin, A., López-Bonetc, E., Cufí, S., Oliveras-Ferraros, C., Del Barco, S., Martin-Castillo, B., et al. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist. Updat. 14 (2011), 212–223.
31. [31] Martin-Montalvo, A., Mercken, E.M., Mitchell, S.J., Palacios, H.H., Mote, P.L., Scheibye-Knudsen, M., et al. Metformin improves healthspan and lifespan in mice. Nat. Commun., 4, 2013.
32. [32] Xie, Q.R.B., Liu, Y.W., Shao, J.X., Yang, J., Liu, T.Y., Zhang, T.T., et al. Male contraceptive Adjudin is a potential anti-cancer drug. Biochem. Pharmacol. 85 (2013), 345–355.
33. [33] Naumova, E., Ubezio, P., Garofalo, A., Borsotti, P., Cassis, L., Riccardi, E., et al. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin. Cancer Res. 12 (2006), 1839–1849.
34. [34] Liu, Q., Zhang, J., Sun, W., Xie, Q.R., Xia, W., Gu, H., Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells. Int. J. Nanomed. 7 (2012), 999–1013.
35. [35] Chen, Y., Gu, H., Zhang, D.S.-Z., Li, F., Liu, T., Xia, W., Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier. Biomaterials 35 (2014), 10058–10069.
36. [36] Liu, Q., Zhang, J., Xia, W., Gu, H., Towards magnetic-enhanced cellular uptake, MRI and chemotherapeutics delivery by magnetic mesoporous silica nanoparticles. J. Nanosci. Nanotechnol. 12 (2012), 7709–7715.
37. [37] Li, X., Gao, C.X., Wu, Y.P., Cheng, C.Y., Xia, W., Zhang, Z.P., Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells. J. Mater. Chem. B 3 (2015), 1556–1564.
38. [38] Foster, S.J., Bruneau, P., Walker, E.R., McMillan, R.M., 2-substituted indazolinones: orally active and selective 5-lipoxygenase inhibitors with anti-inflammatory activity. Br. J. Pharmacol. 99 (1990), 113–118.
39. [39] Bhatia, M., Ramnath, R.D., Chevali, L., Guglielmotti, A., Treatment with bindarit, a blocker of MCP-1 synthesis, protects mice against acute pancreatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 288 (2005), G1259–65.
40. [40] Sironi, M., Pozzi, P., Polentarutti, N., Benigni, F., Coletta, I., Guglielmotti, A., et al. Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Cytokine 8 (1996), 710–716.
41. [41] Sommers, C.D., Thompson, J.M., Guzova, J.A., Bonar, S.L., Rader, R.K., Mathialagan, S., et al. Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation. J. Pharmacol. Exp. Ther. 330 (2009), 377–388.
42. [42] Oh, J.H., Park, E.J., Park, J.W., Lee, J., Lee, S.H., Kwon, T.K., A novel cyclin-dependent kinase inhibitor down-regulates tumor necrosis factor-alpha (TNF-alpha)-induced expression of cell adhesion molecules by inhibition of NF-kappaB activation in human pulmonary epithelial cells. Int. Immunopharmacol. 10 (2010), 572–579.
43. [43] Shao, J., Liu, T., Xie, Q.R., Zhang, T., Yu, H., Wang, B., et al. Adjudin attenuates lipopolysaccharide (LPS)- and ischemia-induced microglial activation. J. Neuroimmunol. 254 (2013), 83–90.
44. [44] Ma, Y., Wang, J., Wang, Y., Yang, G.Y., The biphasic function of microglia in ischemic stroke. Prog. Neurobiol., 2016.
45. [45] Garden, G.A., Moller, T., Microglia biology in health and disease. J. Neuroimmune Pharmacol. Off. J. Soc. NeuroImmune Pharmacol. 1 (2006), 127–137.
46. [46] Xiong, X.Y., Liu, L., Yang, Q.W., Functions and mechanisms of microglia/macrophages in neuroinflammation and neurogenesis after stroke. Prog. Neurobiol. 142 (2016), 23–44.
47. [47] Gonzalez-Scarano, F., Baltuch, G., Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. 22 (1999), 219–240.
48. [48] Hanisch, U.-K., Kettenmann, H., Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10 (2007), 1387–1394.
49. [49] Yenari, M.A., Kauppinen, T.M., Swanson, R.A., Microglial activation in stroke: therapeutic targets. Neurotherap. J. Am. Soc. Exp. NeuroTherapeutics 7 (2010), 378–391.
50. [50] Qin, L., Wu, X., Block, M.L., Liu, Y., Breese, G.R., Hong, J.S., et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55 (2007), 453–462.
51. [51] Ghosh, S., May, M.J., Kopp, E.B., N.F-kappa AND Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16 (1998), 225–260.
52. [52] O'Neill, L.A., Kaltschmidt, C., NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 20 (1997), 252–258.
53. [53] Karin, M., Ben-Neriah, Y., Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18 (2000), 621–663.
54. [54] Sofroniew, M.V., Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 32 (2009), 638–647.
55. [55] Liu, T., Zhang, T., Yu, H., Shen, H., Xia, W., Adjudin protects against cerebral ischemia reperfusion injury by inhibition of neuroinflammation and blood-brain barrier disruption. J. Neuroinflammation, 11, 2014, 107.
56. [56] Prabhakaran, S., Ruff, I., Bernstein, R.A., Acute stroke intervention: a systematic review. JAMA 313 (2015), 1451–1462.
57. [57] Cai, H., Zhang, Z., Yang, G.Y., Preconditioned stem cells: a promising strategy for cell-based ischemic stroke therapy. Curr. Drug Targets 15 (2014), 771–779.
58. [58] Tang, Y.H., Ma, Y.Y., Zhang, Z.J., Wang, Y.T., Yang, G.Y., Opportunities and challenges: stem cell-based therapy for the treatment of ischemic stroke. CNS Neurosci. Therapeutics 21 (2015), 337–347.
59. [59] Jin, R., Yang, G., Li, G., Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J. Leukoc. Biol. 87 (2010), 779–789.
60. [60] Amantea, D., Nappi, G., Bernardi, G., Bagetta, G., Corasaniti, M.T., Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J. 276 (2009), 13–26.
61. [61] del Zoppo, G.J., Milner, R., Mabuchi, T., Hung, S., Wang, X., Berg, G.I., et al. Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke J. Cereb. Circ. 38 (2007), 646–651.
62. [62] Pun, P.B., Lu, J., Moochhala, S., Involvement of ROS in BBB dysfunction. Free Radic. Res. 43 (2009), 348–364.
63. [63] Wang, X., Investigational anti-inflammatory agents for the treatment of ischaemic brain injury. Expert Opin. Investig. Drugs 14 (2005), 393–409.
64. [64] Abbott, N.J., Rönnbäck, L., Hansson, E., Astrocyte–endothelial interactions at the blood–brain barrier. Nat. Rev. Neurosci. 7 (2006), 41–53.
65. [65] Khatri, R., McKinney, A.M., Swenson, B., Janardhan, V., Blood–brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke. Neurology 79 (2012), S52–S57.
66. [66] Bacigaluppi, M., Pluchino, S., Peruzzotti-Jametti, L., Kilic, E., Kilic, U., Salani, G., et al. Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms. Brain J. Neurol. 132 (2009), 2239–2251.
67. [67] Shen, L.H., Li, Y., Chen, J., Cui, Y., Zhang, C., Kapke, A., et al. One-year follow-up after bone marrow stromal cell treatment in middle-aged female rats with stroke. Stroke J. Cereb. Circ. 38 (2007), 2150–2156.
68. [68] Askalan, R., Deveber, G., Ho, M., Ma, J., Hawkins, C., Astrocytic-inducible nitric oxide synthase in the ischemic developing human brain. Pediatr. Res. 60 (2006), 687–692.
69. [69] Bush, T.G., Puvanachandra, N., Horner, C.H., Polito, A., Ostenfeld, T., Svendsen, C.N., et al. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 23 (1999), 297–308.
70. [70] Silver, J., Miller, J.H., Regeneration beyond the glial scar. Nat. Rev. Neurosci. 5 (2004), 146–156.
71. [71] Sofroniew, M.V., Reactive astrocytes in neural repair and protection. Neuroscientist Rev. J. bringing Neurobiol. Neurol. Psychiatry 11 (2005), 400–407.
72. [72] Hudspeth, A.J., How hearing happens. Neuron 19 (1997), 947–950.
73. [73] Nadol, J.B. Jr., Hearing loss. N. Engl. J. Med. 329 (1993), 1092–1102.
74. [74] Mizutari, K., Fujioka, M., Hosoya, M., Bramhall, N., Okano, H.J., Okano, H., et al. Notch inhibition induces cochlear hair cell regeneration and recovery of hearing after acoustic trauma. Neuron 77 (2013), 58–69.
75. [75] Zheng, J.L., Gao, W.Q., Overexpression of Math1 induces robust production of extra hair cells in postnatal rat inner ears. Nat. Neurosci. 3 (2000), 580–586.
76. [76] Zheng, J.L., Gao, W.Q., Concanavalin A protects hair cells against gentamicin ototoxicity in rat cochlear explant cultures. J. Neurobiol. 39 (1999), 29–40.
77. [77] Quan, Y., Xia, L., Shao, J., Yin, S., Cheng, C.Y., Xia, W., et al. Adjudin protects rodent cochlear hair cells against gentamicin ototoxicity via the SIRT3-ROS pathway. Sci. Rep., 5, 2015, 8181.
78. [78] Someya, S., Yu, W., Hallows, W.C., Xu, J., Vann, J.M., Leeuwenburgh, C., et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 143 (2010), 802–812.
79. [79] Haigis, M.C., Sinclair, D.A., Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5 (2010), 253–295.
80. [80] Rine, J., Herskowitz, I., Four genes responsible for a position effect on expression from HML and HMR in Saccharomyces cerevisiae. Genetics 116 (1987), 9–22.
81. [81] Michishita, E., Park, J.Y., Burneskis, J.M., Barrett, J.C., Horikawa, I., Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell 16 (2005), 4623–4635.
82. [82] Vaziri, H., Dessain, S.K., Ng Eaton, E., Imai, S.I., Frye, R.A., Pandita, T.K., et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107 (2001), 149–159.
83. [83] North, B.J., Marshall, B.L., Borra, M.T., Denu, J.M., Verdin, E., The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell 11 (2003), 437–444.
84. [84] North, B.J., Verdin, E., Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One, 2, 2007, e784.
85. [85] Verdin, E., Hirschey, M.D., Finley, L.W., Haigis, M.C., Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem. Sci. 35 (2010), 669–675.
86. [86] Michishita, E., McCord, R.A., Berber, E., Kioi, M., Padilla-Nash, H., Damian, M., et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 452 (2008), 492–496.
87. [87] Ford, E., Voit, R., Liszt, G., Magin, C., Grummt, I., Guarente, L., Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes. Dev. 20 (2006), 1075–1080.
88. [88] Onyango, P., Celic, I., McCaffery, J.M., Boeke, J.D., Feinberg, A.P., SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 13653–13658.
89. [89] Barber, M.F., Michishita-Kioi, E., Xi, Y., Tasselli, L., Kioi, M., Moqtaderi, Z., et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 487 (2012), 114–118.
90. [90] Haigis, M.C., Mostoslavsky, R., Haigis, K.M., Fahie, K., Christodoulou, D.C., Murphy, A.J., et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 126 (2006), 941–954.
91. [91] Liszt, G., Ford, E., Kurtev, M., Guarente, L., Mouse sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J. Biol. Chem. 280 (2005), 21313–21320.
92. [92] Nakagawa, T., Lomb, D.J., Haigis, M.C., Guarente, L., SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 137 (2009), 560–570.
93. [93] Du, J., Zhou, Y., Su, X., Yu, J.J., Khan, S., Jiang, H., et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334 (2011), 806–809.
94. [94] Houtkooper, R.H., Pirinen, E., Auwerx, J., Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 13 (2012), 225–238.
95. [95] Hall, J.A., Dominy, J.E., Lee, Y., Puigserver, P., The sirtuin family's role in aging and age-associated pathologies. J. Clin. Invest. 123 (2013), 973–979.
96. [96] Poulose, N., Raju, R., Sirtuin regulation in aging and injury. Biochim. Biophys. Acta 1852 (2015), 2442–2455.
97. [97] Guarente, L., Calorie restriction and sirtuins revisited. Genes. Dev. 27 (2013), 2072–2085.
98. [98] Kaeberlein, M., McVey, M., Guarente, L., The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes. Dev. 13 (1999), 2570–2580.
99. [99] Chen, D., Guarente, L., SIR2: a potential target for calorie restriction mimetics. Trends Mol. Med. 13 (2007), 64–71.
100. [100] Kanfi, Y., Naiman, S., Amir, G., Peshti, V., Zinman, G., Nahum, L., et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature 483 (2012), 218–221.
101. [101] Satoh, A., Brace, C.S., Rensing, N., Cliften, P., Wozniak, D.F., Herzog, E.D., et al. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab. 18 (2013), 416–430.
102. [102] Chalkiadaki, A., Guarente, L., The multifaceted functions of sirtuins in cancer. Nat. Rev. Cancer 15 (2015), 608–624.
103. [103] George, J., Ahmad, N., Mitochondrial sirtuins in cancer: emerging roles and therapeutic potential. Cancer Res. 76 (2016), 2500–2506.
104. [104] Quan, Y., Wang, N., Chen, Q., Xu, J., Cheng, W., Di, M., et al. SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3 K/Akt pathway. Oncotarget 6 (2015), 26494–26507.